Allogeneic haematopoietic stem-cell transplantation remains the only curative treatment for relapsed/refractory acute myeloid leukaemia (AML) and high-risk myelodysplasia but has previously been limited to patients who achieve remission before transplant. New sequential approaches employing T-cell depleted transplantation directly after chemotherapy show promise but are burdened by viral infection and require donor lymphocyte infusions (DLI) to augment donor chimerism and graft-versus-leukaemia effects. T-replete transplantation in sequential approaches could reduce both viral infection and DLI usage. We therefore performed a single-arm prospective Phase II clinical trial of sequential chemotherapy and T-replete transplantation using reduced-intensity conditioning without planned DLI. The primary endpoint was overall survival. Forty-seven patients with relapsed/refractory AML or high-risk myelodysplasia were enrolled; 43 proceeded to transplantation. High levels of donor chimerism were achieved spontaneously with no DLI. Overall survival of transplanted patients was 45% and 33% at 1 and 3 years. Only one patient developed cytomegalovirus disease. Cumulative incidences of treatment-related mortality and relapse were 35% and 20% at 1 year. Patients with relapsed AML and myelodysplasia had the most favourable outcomes. Late-onset graft-versushost disease protected against relapse. In conclusion, a T-replete sequential transplantation using reduced-intensity conditioning is feasible for relapsed/refractory AML and myelodysplasia and can deliver graft-versusleukaemia effects without DLI.
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The outlook for patients with relapsed or refractory acute myeloid leukaemia (AML) and high-risk myelodysplasia (MDS) is very poor. As targeted cellular immunotherapies, such as chimeric antigen receptor T cells, have not yet been developed for these diseases, allogeneic haematopoietic stemcell transplantation (AHST) remains the only potentially curative therapy, harnessing donor immune-cell mediated graft-versus-leukaemia (GvL) effects to prevent relapse. However, the established strategy of salvage chemotherapy to achieve remission followed by AHST results in 3-year survival rates of only 8-30% for relapsed/refractory AML (Fung et al, 2003; Tavernier et al, 2003; Thomas et al, 2003; Breems et al, 2005; Cook et al, 2006; Mato et al, 2008) . Importantly, these studies report outcomes only for patients who achieved remission prior to AHST, but many patients with relapsed/refractory AML cannot achieve remission and few studies are reported on a full intent-to-treat basis, enrolling patients at onset of salvage therapy rather than at AHST.
Similarly, AHST remains the only curative therapy for MDS (Gangat et al, 2016) . Achieving remission of MDS prior to AHST results in better outcomes (Castro-Malaspina et al, 2008) but this approach is associated with delayed haematological recovery and toxicity that may make successful AHST difficult to deliver.
To address these significant challenges, delivering AHST earlier after induction chemotherapy in AML patients with high genetic risk factors or induction failure have been explored. The German Study Alliance Leukaemia (SAL) group reported the feasibility of this approach in such patients in an initial pilot study (Platzbecker et al, 2006) , followed by a larger retrospective analysis of AHST in patients in aplasia after first induction chemotherapy (Stolzel et al, 2013) , and this strategy was incorporated in the larger prospective SAL AML 2003 study (Schetelig et al, 2015) . In parallel, an approach of delivering chemotherapy to induce remission followed directly by reduced intensity-conditioned (RIC) AHST was first reported by Schmid et al (2005) . This sequential strategy, employing a T-cell depleted transplant platform to reduce toxicity and planned donor lymphocyte infusion (DLI) to strengthen donor immune graft-versus-leukaemia (GvL) effects, resulted in improved outcomes for patients with relapsed/refractory AML and high-risk MDS. Subsequently, several other groups have reported successful application of sequential chemotherapy and AHST using a variety of RIC regimens, confirming the utility of this approach (Liu et al, 2009; Cluzeau et al, 2011; Buchholz et al, 2012; Chemnitz et al, 2012; Saure et al, 2012; Krejci et al, 2013; Schneidawind et al, 2013; Pfrepper et al, 2016) . However, all used T-cell depletion with anti-thymocyte globulin, which increases viral infection after AHST (Hamadani et al, 2009 ) and may increase relapse after RIC regimens (Soiffer et al, 2011) . Most also employed planned DLI, which can be difficult to obtain, especially from unrelated donors.
We have previously reported use of a non-T-cell depleted ('T-replete') RIC-AHST platform in patients with AML in first remission, which results in low toxicity, very infrequent viral infection and a low requirement for DLI (Taussig et al, 2003; Davies et al, 2006 Davies et al, , 2013 . We therefore reasoned that incorporation of this transplant approach in a sequential strategy might be feasible and could potentially reduce infectious problems and the need for DLI. We now report the results of a prospective Phase II clinical trial of sequential chemotherapy and T-replete AHST using our established RIC platform for patients with relapsed/refractory AML and highrisk MDS.
Methods

Study design and eligibility
We performed a prospective single-centre Phase II clinical trial of sequential chemotherapy and T-replete RIC-AHST. Patients with relapsed or refractory AML, high-risk MDS (International Prognostic Scoring System Intermediate 2/high; Greenberg et al, 1997) or other high-risk myeloid malignancy were eligible for the study. The study enrolled 53 patients, 47 of whom had AML/MDS. To facilitate comparison with published sequential studies, only AML/MDS patients are included in this report. Patients with functionally refractory AML [those not entering complete remission (CR, <5% bone marrow blasts) after one cycle of induction therapy or remitting but relapsing with a first CR (CR1) shorter than 6 months] were grouped together as outcomes for these two groups are very similar (Breems et al, 2005) . The protocol was approved by the local ethics committee with written informed consent obtained in accordance with the Declaration of Helsinki. The primary study endpoint was overall survival (OS). Secondary endpoints included engraftment, chimerism, treatment-related mortality (TRM), acute and chronic graft-versus-host disease (GvHD), disease response/ relapse and use of DLI.
Sequential chemotherapy and reduced-intensity T-replete conditioning protocol
Patients received daunorubicin 45 mg/m 2 (Days À15 to À13) and cytarabine 1500 mg/m 2 twice daily (Days À15 to À9) followed by fludarabine 25 mg/m 2 (Days À6 to À2) and cyclophosphamide 1 g/m 2 (Days À3 and À2, as previously reported (Davies et al, 2013) . Donors were fully human leucocyte antigen (HLA)-matched by high resolution typing at HLA-A, -B, -C, -DRB1 and DQB1 loci. All patients received granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells except one, who received unmanipulated bone marrow. GvHD prophylaxis was methotrexate (5 mg/m 2 on Days +1, +3 and +6), and the calcineurin inhibitor (CNI) ciclosporin (CSA) adjusted to maintain therapeutic trough blood levels of 150-300 lg/l. Tapering of CSA commenced at Day +90 in the absence of GvHD and earlier in patients with <80% donor chimerism at Day +60. Supportive care is detailed in the Supplemental Methods.
Engraftment, chimerism and DLI
Neutrophil recovery was defined as time to a count of 0Á5 9 10 9 /l for two consecutive days. Chimerism was performed on whole peripheral blood and purified CD3 + T-cells by polymerase chain reaction analysis of variable number tandem repeat polymorphisms monthly to Day +90 and thereafter as clinically appropriate. Full donor chimerism was defined as greater than 95% donor. DLI was not planned but could be used at investigators discretion for mixed chimerism or disease relapse.
Definitions, outcomes and statistical analyses
Treatment-related mortality was defined as death from any cause in the absence of disease persistence/relapse. Acute and chronic GvHD were diagnosed/graded using consensus/ National Institutes of Health criteria and managed by institutional protocol (Przepiorka et al, 1995; Filipovich et al, 2005) . Differences in pre-transplant variables were assessed using the two-sided Fisher's exact test (FET). Initial disease response was assessed by bone marrow biopsy at Day +30.
Patients with persistent disease were censored at this day for relapse. OS curves were constructed using the method of Kaplan and Meier (1958) and differences between groups were assessed using the log-rank statistic (Peto et al, 1977) . Patients were censored at last follow-up in January 2015. For donor chimerism, TRM, GvHD and disease persistence/relapse, cumulative incidence with competing risks was calculated using the method of Fine and Gray (1999) . Data were analysed using SPSS v22.0 (IBM, New York, NY, USA) and Stata 12 (StataCorp, College Station, TX, USA). Additional statistical considerations are given in the Supplemental Methods.
Results
Patient, donor and graft characteristics
Forty-seven patients with AML/MDS were enrolled between 2007 and 2014. Four patients did not undergo transplantation; two had donors deemed unfit to donate by donor registries and no alternate donors could be identified, and two died prior to AHST, one from infection and one from AML. Consequently, 43/47 (92%) patients proceeded to AHST as per protocol. Details of transplanted patients, donor and graft characteristics are summarized in Table I . AML patients received primary induction therapy, mostly as directed by the UK Medical Research Council AML study current at the time of their induction [standard ADE (cytarabine, daunorubicin, etoposide)/DA (daunorubicin, cytarabine) or FLAGIda (fludarabine, cytarabine, G-CSF, idarubicin) on AML15 or DA with daunorubicin 60 mg/m 2 or 90 mg/m 2 on AML17]. All patients had bone marrow blasts >5% at the time of study entry. All patients with relapsed AML had a Breems' score of seven of higher (Breems et al, 2005) . Patients were transplanted using HLA-matched related (n = 21) or unrelated donors (n = 22).
Engraftment and chimerism
Five patients died of infection or multi-organ failure by Day +15, prior to engraftment. Of the remaining 38 patients, all engrafted. The median time of neutrophil engraftment was Day +21 (range +11 to +29). At the earliest time point where donor chimerism was evaluated (Day +30), the median unsorted donor chimerism level was 96%, with 71% of patients achieving 90% or higher and less than 25% of patients achieving less than 80% donor chimerism. After tapering CSA, most patients who had mixed chimerism at earlier time points converted to full donor chimerism without need for DLI, with a median unsorted donor chimerism level of 98% and only 12% of patients with less than 80% donor chimerism in unsorted peripheral blood at Day +180 (Fig 1A) . Similarly, T-cell lineage-specific donor chimerism levels were high, even at early time points (median 94% with only 12% of patients achieving less than 80% donor T-cell chimerism at D + 30) with most patients with lower levels converting to full donor T-cell chimerism (FTTC) upon tapering CSA, with a median level of 96% and only 10% of patients with less than 80% donor T-cell chimerism in peripheral blood at Day +180 (Fig 1B) . Graft failure (in the absence of disease persistence or relapse) occurred in only two patients; one patient had autologous reconstitution and successfully underwent a second RIC AHST, and one patient died with aplasia induced after tapering CSA.
Overall survival
At the time of data analysis, 15 of 43 (35%) transplanted patients were alive with a median follow-up of surviving patients of 4 years. The actuarial OS and 95% CIs for transplanted patients was 45% (29-61%), 39% (24-54%) and 33% (18-48%) at 1, 2 and 3 years respectively (Fig 2A) . One surviving patient relapsed and underwent a second RIC AHST and is currently in remission. No surviving patients had relapsed disease at the point of data analysis so current disease-free survival was equal to OS. OS was most favourable in patients with MDS or with relapsed AML, with a 2-year OS of 71% and 52% respectively (Fig 2B, C) . For AML patients, there was a trend toward better OS in patients with intermediate-risk cytogenetics at diagnosis compared to those with high-risk cytogenetics (2-year OS of 44% vs. 20% respectively, P = 0Á09). No other pre-transplant patient or donor factors listed in Table I significantly impacted on OS.
To capture the true outcome of the whole patient group, we performed survival analysis on an intention-to-treat basis on all AML/MDS patients enrolled in the study, not just those who proceeded to RIC AHST. The OS of all patients (from the date of study entry) was 43%, 36% and 30% at 1, 2 and 3 years respectively (Fig 1D) .
Toxicity and GvHD
Of transplanted patients, 17 died from TRM and the cumulative incidence of TRM with relapse as a competing risk was 35% and 40% at 1 and 3 years respectively (Fig 3A) . The cumulative incidence of TRM was significantly higher in older patients (those above the median age of 53 years, Fig 3B) but was not significantly impacted upon by the Haematopoietic cell transplant-co-morbidity Index (HCT-CI) or other pre-transplant patient or donor factors. The cumulative incidence of classical acute GVHD was 24% (grade 2-4) and 7% (grade 3-4) occurring at a median Day +47. Cumulative incidence of late onset acute/chronic GvHD was 52% of assessable patients, occurring at a median Day +159 (Fig 3C, D) . The majority of these patients had extensive chronic GvHD requiring systemic immunosuppression. A total of seven deaths were attributable to either acute or chronic GvHD. Ten patients died from regimen-related toxicity without GvHD (8 of bacterial infection and 2 of multiorgan failure).
Viral reactivation, viral disease
Only 10 of 43 transplanted patients (23%) had one or more episodes of cytomegalovirus (CMV) reactivation, (Burnett et al, 2015) . †Untreated AML with prior history of cytotoxic chemotherapy exposure. ‡Six patients with AML had undergone prior reduced intensity chemotherapy-AHST and one patient had Bu-Cy autograft. §Sex mismatch defined as female donor, male recipient. ¶Higher risk = donor and/or recipient cytomegalovirus seropositive pre-transplant. **910 6 cells/kg. † †Includes the single patient who received human leucocyte antigen-matched bone marrow from a related donor containing 10 9 10 6 CD3 + T-cells/kg. 
T-Replete Sequential Allotransplantation for AML/MDS
DLI
No patients received DLI.
Disease response and relapse
Of transplanted patients, 38/43 were alive at Day +30 and evaluable for disease response, of which 32 had a bone marrow evaluation at this time point. Three of 32 had persistent disease (and were censored as disease relapse at this time point) and 29/32 (91%) were in CR. The six patients not assessed at Day +30 had normal count recovery with predominantly donor cell chimerism and were therefore presumed to be in CR. A further nine patients relapsed and the cumulative incidence of relapse was 30% at 3 years. The median time to relapse was 95 days. At the time of analysis no patient has relapsed after 2 years ( Fig 4A) . The cumulative incidence of relapse was significantly higher in patients with functionally refractory AML than in relapsed AML or MDS, and in patients receiving below the median dose of CD34 + cells compared to those receiving above the median dose (Fig 4B, C) . In contrast, the cumulative incidence of relapse was not significantly different in AML patients grouped by cytogenetic risk-group (at diagnosis) or for all patients grouped by infused CD3 + T-cell dose ( Figure S1A , B). Only one of 13 patients transplanted with relapsed AML went on to relapse post-sequential transplant and six of these patients achieved an inversion of remission length, with a longer second CR than CR1 (Fig 4D) .
Impact of post-transplant factors influencing GvL effects on outcome
Finally, we assessed the impact on disease relapse of three post-transplant factors that might influence the development of donor immune cell mediated GvL effects: post-transplant T-cell chimerism levels, CNI exposure and clinical alloreactivity in the form of late onset acute/de novo chronic GvHD. Individual T-cell chimerism patterns (Fig 5A) are grouped according to outcome (ongoing CR, relapse or TRM). There was no significant difference in the level of T-cell chimerism (one way ANOVA) or in the proportion of patients achieving full donor T-cell chimerism (FET) at any single individual time point between these groups. However, all patients in ongoing CR (14/14) achieved full donor T-cell chimerism vs only 6/9 patients who achieved CR post-transplant but subsequently relapsed (P = 0Á047 FET). These data are consistent with the attainment of full donor T-cell chimerism posttransplant being necessary, but not sufficient, to provide a sustained GvL effect capable of protecting against relapse. In view of this we examined the impact of immunosuppression early post-transplant, which could modulate development of T-cell mediated GvL effects. We used an area under the curve analysis to quantify CNI exposure over the first 21 days post-transplant (AUC 21 ) in patients who survived to this time point. The degree of CNI exposure (AUC 21 ) over this period did not impact the achievement of full donor T-cell chimerism or the development of early acute GvHD whilst on CNI ( Figure S2A, B) . However, early CNI exposure was significantly lower in patients who went on to develop clinical alloreactivity after tapering CNI compared to those who did not, demonstrating that T-cell alloresponses mediating delayed GvHD/GvL effects are impacted by immune modulation early post-transplant in this setting (Fig 5B) . We finally assessed the impact of the development of clinically apparent alloreactivity after CNI withdrawal on subsequent relapse. A landmark analysis of cumulative incidence of relapse (with TRM as a competing risk) of patients alive and in remission at Day +100 is shown in Fig 5C . In such patients, late onset acute/de novo chronic GvHD after the attainment of full donor T-cell chimerism was associated with a significant reduction in subsequent relapse (Fig 5B) , demonstrating that late onset clinical alloreactivity was associated with provision of immune GvL effects. This effect was most prominent in patients with AML, resulting in significantly better OS (Fig 5D) .
Discussion
In the last decade the application of sequential chemotherapy and AHST strategies for AML/MDS have led to better outcomes than historical approaches, but all have all used T-cell depletion, mostly followed by planned DLI. The ability to deliver a sequential approach using a T-replete transplant platform without planned DLI has not previously been reported and is of considerable interest, as T-cell depletion is associated with more viral infections, and DLI can be difficult to obtain from unrelated donors and exposes donors and patients to additional medical procedures. In this study we demonstrate that sequential chemotherapy and T-replete RIC AHST results in high levels of donor chimerism without any use of DLI and very little morbidity from viral infection, and can result in durable remissions, particularly in patients with relapsed AML or MDS.
A major potential advantage for using a T-replete transplant platform is that high levels of donor chimerism, particularly T-cell chimerism, can be achieved spontaneously without DLI, whereas persistent split chimerism, particularly in the T-cell lineage, is common after T-cell depleted approaches and DLI is more frequently required to augment chimerism levels (Dey et al, 2003; Shaw et al, 2007) . Previous early AHST or sequential AHST strategies for relapsed/refractory AML have used T-cell depletion either for all patients (Schmid et al, 2005; Cluzeau et al, 2011; Buchholz et al, 2012 ; Chemnitz et al, 2012; Krejci et al, 2013; Pfrepper et al, 2016) or for patients receiving transplants from unrelated donors (Platzbecker et al, 2006; Liu et al, 2009; Saure et al, 2012; Stolzel et al, 2013; Schetelig et al, 2015) with the majority administering planned DLI. In contrast, almost all of our assessable patients achieved full donor chimerism spontaneously despite the truly non-myeloablative conditioning employed. Furthermore, we also observed the achievement of high levels of donor T-cell chimerism, which has been reported to be key in prevention of relapse after RIC-AHST (Saito et al, 2008; van Besien et al, 2009) , suggesting that a GvL effect may be established spontaneously without DLI after our approach.
Although direct comparison of outcomes from our study with those of other early AHST or sequential transplant approaches is not possible, the 2-year OS of transplanted patients (39 AE 15%) we report is comparable to outcomes reported by the SAL study group of early AHST (Stolzel et al, 2013; Schetelig et al, 2015) and to both individual reports of different individual sequential strategies using either FLAMSA (FLAG + amsacrine) or clofarabine-based chemotherapy followed by cyclophosphamide and low dose total body iradiation (Schmid et al, 2005) or busulphanbased RIC platforms (Schneidawind et al, 2013; Mohty et al, 2017) , and to the pooled outcome data from a recently published registry-based survey by the European Society for Blood and Marrow Transplantation (EBMT) of patients with AML treated with sequential chemotherapy and AHST (Ringden et al, 2017) . In the latter series, the authors report that the 3-year OS of patients treated with T-cell depleted approaches was superior to that of those who received T-cell replete transplants (31% vs. 20%). However it should be noted that only a small minority of patients in this series received T-replete transplants, reflecting current sequential practice, and our current study provides a much larger patient group to assess the impact of T-replete transplantation on sequential strategies for AML/MDS. Importantly, published data for sequential AHST for AML/ MDS is restricted to outcome of patients who proceed to transplant rather than the outcome of the patient group for whom the treatment is intended. Furthermore, the SAL AML 2003 study utilizing early AHST in patients with refractory AML demonstrated a survival benefit for early AHST, but low proportions of eligible patients with available donors proceeded to early AHST (Schetelig et al, 2015) . In contrast, over 90% of AML patients in our study proceeded to AHST as per protocol. Additionally, we provide important new data demonstrating that the 3-year OS for all AML/MDS patients enrolled on our study on an intention to transplant basis is 30%.
Although we had a strikingly low frequency of CMV disease, our approach was, however, associated with somewhat higher overall TRM (40%) than that reported in sequential strategies utilizing T-cell depletion (20-33%) and in the recent EBMT series of pooled registry data (26%). In order to develop strategies to address this we performed an analysis of risk factors for TRM. Although we did not see a clear association of TRM with HCT-CI (which is validated across most AHST platforms, but not yet in the context of sequential approaches), we did see significantly higher TRM in older patients who tended to have higher HCT-CI scores. This suggests that a stratified approach to patient selection may help reduce TRM to better apply our T-replete sequential approach in the future.
Interestingly, we observed the most favourable outcomes for AML patients in those with relapsed disease, and our approach was less effective in patients with functionally refractory AML, which contrasts with reports of FLAMSAbased strategies, which can be particularly effective in the latter patient group (Schmid et al, 2006) . This difference is likely to reflect the lower level of direct anti-leukaemic activity in our induction chemotherapy and RIC-platform (which is truly non-myeloablative) and thus our approach may offer less effective protection from disease persistence/relapse in the early post-transplant period. However, our strategy was more effective in patients with relapsed AML and MDS, with very low incidences of relapse and favourable OS. Notably, patients with relapsed AML included in our report all had high Breems' scores (Breems et al, 2005 ) predicting a 5-year OS of 4-18%. Although the number of patients with relapsed AML in our study is small, the 5-year OS observed in these patients (43%) suggests our approach is superior to historical approaches to treatment for this patient group.
The demonstration of a clear association with spontaneous GvHD after tapering immunosuppression and protection from relapse indicates the potential for our strategy to deliver a potent GvL effect and is further evidence that the strategy might be more effective in relapsed rather than primary refractory AML. Our analysis of chimerism patterns and outcome demonstrate that a high level of T-cell lineage-specific chimerism is necessary, but not sufficient, for a clinically significant GvL effect. Importantly, although early exposure to CNI in the first 3 weeks post-transplant did not impact on T-lineage chimerism, increased early CNI was associated with a reduced frequency of subsequent GvHD, suggesting that the GvL effect may be tractable in this context by modulation of immunosuppression. Although there is undoubtedly a burden of morbidity that comes with chronic GvHD, in our previous experience using a T-replete RIC approach for AML most patients with chronic GvHD required systemic immunosuppression for less than a year (Davies et al, 2013) , and studies have shown quality of life is comparable after either T-cell depleted or T-replete AHST (Lee et al, 2002) .
In summary, we report a strategy of sequential chemotherapy and T-replete RIC-AHST for relapsed/refractory AML/ MDS that demonstrates comparable outcomes to published series of T-cell depleted approaches without requirement for DLI, which is a major practical advantage particularly in the unrelated donor setting. This approach should be considered for incorporation into new Phase III comparative studies to define the best strategy of sequential chemotherapy and AHST for management of relapsed/refractory AML. 
